Senores Pharmaceuticals Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/89rdwdpin63im0f84dbht7cl.pdf

Key Takeaways


Regulated Markets (US) Performance

Deval Shah: "I think last quarter also we said that this 44% was a one-off, I think due to some product mix and other mix of income. But sustainable margin, what we see, gross margin, EBITDA margin for the US business is around 40%."

Apnar Pharma Acquisition

Swapnil Shah: "It is very early to say what kind of margin expansion that will happen from Apnar as we speak. However, we see margins expanding in when we reach that optimal number of utilization of that facility."

Emerging Markets Turnaround


India Branded Generics & CDMO


Financial Position & Cash Flows


Guidance & Commitments

CommitmentSpecificsTimeline
FY26 top-line growth50% growth over FY25FY26 full year
FY26 PAT growth100% growth over FY25FY26 full year
FY26 consolidated EBITDA marginReach roughly 30% blendedBy end of FY26
Apnar revenue contribution₹120–₹150 croreFY27
India branded generics revenue₹80+ croreFY27
Emerging markets revenue₹170–₹180 croreFY27
Regulated markets own-product/CDMO mixRoughly 60/40FY27
ANDA launches from approved pipelineAll 28 approved yet-to-be-launched ANDAsNext 6–8 quarters
ANDA launches from development pipelineAt least 10 of 22 ANDAs under developmentNext 6–8 quarters
Controlled substance launchesTwo launchesFY27
Emerging markets EBITDA marginStabilize at 18%, then 20%–22%FY27, then further improvement over 3–4 quarters
CapexRoughly ₹50–₹100 croreNext 2–3 years
Minimum growth target25% plus (can be better)FY27

Key Metrics

MetricQ3 FY26
Consolidated revenue₹175 cr, +64% YoY
Regulated markets revenue₹113 cr, +60.5% YoY
Emerging markets revenue₹38 cr, +47.5% YoY
India branded generics revenue₹10.5 cr, over 6x YoY
Consolidated EBITDA₹54 cr, +86% YoY
Consolidated EBITDA margin30.9%, +360 bps YoY and +30 bps QoQ
PAT after minority interest~₹32 cr, ~85% YoY growth
9M FY26 consolidated revenue₹474 cr, +65% YoY
9M FY26 EBITDA margin29%, +340 bps YoY
9M FY26 PAT margin17.7%, +350 bps YoY
9M FY26 operating cash flow~₹51 cr, significant improvement over last year
Approved ANDAs46, covering 137+ product trends, nearly quadrupled from 12 in Dec 2024
ANDAs launched18 launched; 28 approved with 100+ strengths available for launch
ANDAs under development22 molecules with 50+ strengths
CDMO-CMO commercial products16 products, 55+ strengths
Emerging market registered products450 as of Dec 2025; 56 new approvals in Q3; 850+ under registration
Emerging market per unit metric~₹2 per unit
Regulated market revenue mix~55% own products, ~45% CDMO/CMO; full year expected ~60%/40%
Controlled substance revenue contribution~15%–20% of overall revenue
Apnar Pharma acquisition stake75% completed; balance 25% expected by Q2 FY27
Apnar expected revenue contribution$16–$18 million in next 12–15 months from 5 approved ANDAs
India branded generics FY26 guidance₹40–₹50 cr
Emerging markets FY27 revenue guidance₹170–₹180 cr
US-regulated business sustainable EBITDA margin~40%
Emerging markets EBITDA margin targetupwards to close to 20% at peak; FY27 expectation 18%–22%
Net working capital cycle~90–94 days
Capex expectation next 2–3 years₹50–₹100 cr